Haya Therapeutics Company

Haya Therapeutics focuses on blocking long non-coding RNAs found in the human genome, which play a role in fibrotic diseases and other age-related health conditions, like cancer. Haya aims to identify new targets and drug candidates that could be more effective and have a greater efficacy profile than current treatments. The precision therapeutics company uses RNA-targeting drugs, such as modified antisense oligonucleotides, to inhibit long non-coding RNAs.
Technology: Gene Therapy
Industry: BioTech
Headquarters: Lausanne
Founded Date: 2017
Employees Number: 1-10
Investors Number: 8
Total Funding: 20328986
Last Funding Date: 2021
Last Funding Type: Seed

Visit Website
Register and Claim Ownership